Prosecution Insights
Last updated: April 19, 2026

Examiner: LIEB, JEANETTE M

Tech Center 1600 • Art Units: 1654 1675

This examiner grants 80% of resolved cases

Performance Statistics

79.9%
Allow Rate
+19.9% vs TC avg
805
Total Applications
+16.8%
Interview Lift
1024
Avg Prosecution Days
Based on 780 resolved cases, 2023–2026

Rejection Statute Breakdown

3.0%
§101 Eligibility
14.7%
§102 Novelty
37.4%
§103 Obviousness
15.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18458690 OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY Non-Final OA The Regents of the University of California
17926479 METHODS FOR TREATING PLASMA PROTEIN IMBALANCES OR DEPLETION Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18047135 VIP Antagonists and Uses in Treating Cancer Non-Final OA Georgia Tech Research Corporation
18345975 BOTULINUM NEUROTOXIN-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING Final Rejection REGENERON PHARMACEUTICALS, INC.
18339305 Buffered Formulations Of Exendin (9-39) Non-Final OA The Board of Trustees of the Leland Stanford Junior University
17757058 RETINA REGENERATION THROUGH EPIGENETICS MANIPULATION Non-Final OA Baylor College of Medicine
17779072 COMPOSITIONS AND METHODS FOR USE IN TYPE 1 DIABETES Non-Final OA The Research Foundation for The State University of New York
17761854 BACTERIOCINS FOR CONTROL OF SALMONELLA ENTERICA Final Rejection Nomad Bioscience GmbH
18498452 BRANCHED PEPTIDES FOR ENZYMATIC ASSEMBLY AND MITOCHONDRIA DRUG DELIVERY Final Rejection BRANDEIS UNIVERSITY
18146958 SWEET PROTEIN MUTANTS FROM TRUFFLE Non-Final OA MYCOTECHNOLOGY, INC.
17482273 METHODS FOR TREATING SEVERE ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R INHIBITOR Final Rejection SANOFI BIOTECHNOLOGY
17638761 MODIFIED TFF2 POLYPEPTIDES Non-Final OA TONIX PHARMA LIMITED
18036329 CELL-PENETRATING PEPTIDES Non-Final OA FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA
18035707 A COMPOSITION COMPRISING EXTRA-CELLULAR VESICLES FROM MESENCHYMAL STEM CELLS AND ALPHA-1 ANTITRYPSIN FOR THE TREATMENT OF VIRAL INFECTIONS Non-Final OA AATEC MEDICAL GMBH
18312574 METHOD FOR TREATMENT OF DRY EYE COMPRISNG APPLYING P55PIK INHIBITOR Non-Final OA Wuhan Yicheng Biological Technology Co., Ltd.
18251652 POLYPEPTIDES FOR USE IN THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES Non-Final OA IMMUNE SYSTEM KEY LTD.
17801514 ALPHA-CARBONYL ALKENYL ESTER PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Non-Final OA JIANGXI NORMAL UNIVERSITY
17800994 TREATMENT OF MEDICAL INDICATION Non-Final OA VALLAURIX MC S.A.R.L.
17638988 DRUG CONTAINING TARGETING LIPOSOMES Final Rejection NEXTAR CHEMPHARMA SOLUTIONS LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month